R&D

An ‘obligation to rebound’: Biogen backs further away from aducanumab as R&D team hunts down late-stage M&A opportunities

Staggered by a disaster for their Alzheimer’s drug aducanumab, Biogen today took another unsteady step back away from their big focus on the memory-wasting disease as the CEO started to talk up the diversity of its pipeline.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->